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ABSTRACT 
 
Background and Objectives: Cardiac remodelling may be defined as genome expression, molecular, cellular and 
interstitial changes that are apparently changes in size, shape and function of the heart after cardiac injury. Type-2 
diabetes is associated with significantly higher risk of heart failure (HF), coronary artery disease (CAD) and cardiac 
remodelling. Present study was aimed as to evaluate the Pharmacological and biochemical effects of Talc in 
doxorubicin induced cardiac remodelling in Wister rat. Method: Albino Wistar Rats (100-150gm) were divided into 
8 groups (n=6), cardiac remodelling were induced Doxorubicin with a 2.0 mg/kg i.p. twice in a week for 20 weeks) 
and oral dose of talc (0.14mg/kg) for the period of 20 weeks and treated with Paracetamol for 5 day.Result and 
Conclusion: Exposure of Doxorubicin and Talc altered all biochemical parameter as Blood glucose, Triglyceride, 
CRP and Troponin-T etc. In conclusion, it was clear that talc may promotecardiac remodelling in Wistar rats. 
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Introduction 
 
Remodelling is defined as alteration in the structure 
(dimensions, mass, shape) of the heart (called cardiac 
or ventricular remodelling) in response to 
hemodynamic load and/or cardiac injury in association 
with neuro-hormonal activation [1, 2]. The cardiac 
cells involved in the remodelling process are 
cardiomyocytes and fibroblasts. Fibroblast stimulation 
increases collagen synthesis and causes fibrosis of both 
the infarcted and non- infarcted regions of the ventricle 
[3]. This leads to a loss of cardiomyocytes by apoptosis 
or necrosis. Eventually these cardiomyocytes are 
replaced by fibroblasts and extracellular collagen. 
Doxorubicin (DOX), an anthracycline has been widely 
used in the treatment of all forms of cancer but its use 
is limited due to its toxicity effect especially on the 
cardiac tissues. The Doxorubicin induced 
cardiotoxicity has been shown to be mediated   
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through different mechanisms, including membrane 
lipid peroxidation, ROS formation and mitochondrion 
damage [4]. Due to the lack of developed antioxidant 
defence system, these free radicals produced by 
electron transfer from the semiquinone to quinine 
moieties of the anthracyclinethat are responsible for 
myocardial damage and subsequent doxorubicin 
induced cardiotoxicity[5].Paracetamol (known as 
acetaminophen in the United States) is one of the most 
commonly used non-steroidal anti-inflammatory drugs 
(NSAIDs) [6]. It is a rapid, reversible, non-competitive 
inhibitor of cyclooxygenase activity (Cox-3) in the 
brain and spinal cord and thus products of the 
arachidonic acid cascade; acetaminophen has been 
available since the 1950s as an over-the-counter 
product for pain and fever relief. Although its 
metabolism is quite well understood, the mechanism of 
acetaminophen toxicity remains somewhat a mystery 
with recent evidence suggesting that multiple cytotoxic 
pathwayis involved. Paracetamol is a widely used 
analgesic and antipyretic drug [7].Talc is defined as 
hydrous magnesium silicate, Mg3Si4O10(OH)2 consists 
of a brucite sheet containing magnesium ions pack 
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between two silica sheets which are held mutually by 
relatively weak forces and belongs to the silicate 
subclass phyllosilicate and the clay group 
montmorillonite/smectite.  Nickel and iron a variety of 
elements may be included in the talc particle lattice but 
are so bound within the particle that they are not free to 
exert any biological action [8].In the review of 
pharmaceutical excipients, Golightlyet al.(1988) state, 
"Ingestion of talc is very unlikely to be toxic[9]."Our 
previous result was based on the pharmacological 
action of excipient in anticancer drug, have given an 
influence that Talc may induced Type-2 diabetes [10]; 
Diabetes accounted for a significant percentage of 
patients with a diagnosis of heart failure in numerous 
epidemiologic studies [11]. The United Kingdom 
Prospective Diabetes Study [12], Cardiovascular 
Health Study [13], and Euro Heart Failure Surveys [14] 
all suggested that the presence of diabetes may 
independently increase the risk of developing incident 
heart failure; Thus Cardiac remodelling protocol was 
designed.Albino Wistar male/female rats weighing 
about 100-150 gm, were procured from Siddhartha 
institute of pharmacy, Dehradun. The Albino Wistar 
rats were housed under temperature (25 ± 2ºC) and 
relative humidity (30-70%) with a 12:12 light-dark 
cycle, and acclimatized in the animal house facility of 
the department under ambient condition. The animals 
were fed with standard semi purified diet and water. 
All the experiments on animals were conducted in 
accordance with the internationally accepted principles 
for laboratory animal use and as per the experimental 
protocols duly approved by the Institutional Ethical 
Committee (IAEC No. 1435/PO/a/11/CPCSEA) with 
the project approval no- “SIP/IAEC/02/2014” by the 
Institutional Animal Ethical Committee (IAEC) of 
Siddhartha College of pharmacy, Dehradun. The rats 
were acclimatized and randomly divided into 08 groups 
and each group have 6 rats; (1)Normal control (NC) - 
Rats were administered with normal diet and were not 
given any treatment during the research study. (2)DOX 
Control-Rats of this group were administered 
Doxorubicin with a 2.0 mg/kg i.p. twice in a week for 
20 weeks(3)Talc control- Rats of this group were 
administered with Talc with a 0.14mg/kg oral dose for 
20 weeks[10]. (4)PCM control- Rats of this group 
were administered with normal diet for 20 weeks and 
after that were given PCM (500 mg/kg/d) for 5 
days.(5)DOX +Talc control- Rats of this group were 
administered Doxorubicin with a 2.0 mg/kg body 
weight i.p. twice in a week and also administered Talc 
with a 0.14mg/kg oral dose for 20 weeks. (6)DOX 
+PCM control- Rats of this group were administered 
Doxorubicin with a2.0 mg/kg body weighti.p. twice in 
a week and were given PCM (500 mg/kg/d) for 5 days. 
(7)Talc+PCM control- Rats of this group were 
administered Talc with a 0.14mg/kg oral dose for 20 
weeks and were given PCM (500 mg/kg/d) for 5 days. 
(8)DOX+Talc+PCM control- Rats of this group were 
administered Doxorubicin with a2.0 mg/kg body 
weighti.p. twice in a week and administered Talc with 
a 0.14mg/kg oral dose for 20 weeks and were given 
PCM (500 mg/kg/d) for 5 days. 
Induction of cardiac remodelling 
Cardiac remodelling was induced by a Doxorubicin 
dose of 2.0 mg/kg body weight twice in a week. 
 
Determination of biochemical parameters 
Isolation of Serum 
At the end of the treatment period, animals were fasted 
overnight. Blood sample was collected on termination 
of the experiment from retro-orbital plexus under light 
ether anesthesia without any anticoagulant and allowed 
to stand for 30 minutes at room temperature then 
centrifuged at 250 rpm for 10 minutes to separate the 
serum. The serum obtained was kept at 2ºC -4ºC until 
used. 
Blood glucose measurement using Glucometer 
Blood glucose was measured using digital glucometer. 
Drop of blood was placed on one side of test strip that 
was inserted in the glucometer. The glucose level was 
displayed on to the screen within 20 seconds. 
C-reactive protein 
The levels of C-reactive protein (CRP) are enhanced by 
HF. Higher C-reactive protein predicts worse prognosis 
in acute heart failure only in non infected patients. 
Recent studies have reported a potential added-value of 
CRP for the risk prediction of adverse clinical events 
independently of natriuretic peptides. The potential 
advantage of CRP testing is its availability within the 
majority of laboratories through automated assays. 
Troponin-T 
Cardiac troponin T (cTnT) was measured on Elec-sys 
2010 Immunoassay System (Roche Diagnostics, 
Indianapolis, IN). The method employs two 
monoclonal antibodies specifically directed against 
human cardiac troponin T, with 
electrochemiluminescent detection. This is a recent, 
sensitive third-generation assay standardized with 
human recombinant cTNT, with a limit of detection of 
0.01 ng/ml. 0.1 ng/ml is recommended as the clinical 
threshold value, above which damage to the 
myocardium can be assumed. 
Statistical analysis 
Statistical analysis was carried out using Graph Pad 
Prism 5.0 (Graph Pad Software, San Diego, CA, 
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USA).The results were expressed as mean ± SEM. 
Statistical significance between more than two groups 
was tested using one-way ANOVA followed by 
Tukey's multiple comparison tests. The p values less 
than 0.001 were considered significant. 
 
Results 
 
Blood Glucose 
The DOX control were showed not significant (ns) 
effect and Talc control were displayed significantly 
increased (p<0.001) result of Blood glucose as 
compared to NC group. On the other hand Talc treated 
groups displayed significantly elevated level (p<0.001) 
of blood glucose as compared to DOX Control group; 
while PCM control were showed not significant (ns) 
level of blood glucose when compare with DOX 
control group(Table no. 1). 
Triglyceride 
The DOX control were displayed not significant (ns) 
effect and Talc control were displayed significantly 
upward (p<0.001) level of Triglyceride as compared to 
NC group. On the other hand Talc control and 
Talc+PCM control were illustrated significantly 
elevated level (p<0.001) of Triglyceride as compared 
to DOX Control group; while PCM control and 
DOX+Talc control were showed not significant (ns) 
level of Triglyceride and DOX+Talc+PCM control 
were demonstrated significant (p<0.05) level of 
Triglyceride when compared to DOX Control 
group(Table no. 1). 
Total Cholesterol (mg/dl) 
The DOX control and Talc control were displayed 
significant (p<0.001) level of Total Cholesterolas 
compared to NC group while Talc control and 
DOX+Talc control, Talc+PCM control and 
DOX+Talc+PCM control were displayed significantly 
increased (p<0.001) level of Total Cholesterolas 
compared to DOX Control. DOX+PCM control were 
demonstrated not significant (ns) level of Total 
Cholesterolas compared to DOX Control(Table no. 2). 
Creatinine (mg/dl) 
The DOX control and Talc control were displayed 
significantly upward (p<0.001) level of Creatinineas 
compared to NC group. Talc control and DOX+Talc 
control were showed not significant (ns) level of 
Creatinineas compared to DOX Control while PCM 
control, DOX+PCM control and Talc+PCM control 
were displayed significant (p<0.001) level of 
Creatinineas compared to DOX Control. In 
DOX+Talc+PCM control were demonstrated 
significantly decreased level (p<0.05) of 
Creatininewhen compared to DOX Control(Table no. 
1). 
HDL (mg/dl) 
The DOX control and Talc control were displayed 
significantly downward (p<0.001) level of HDL as 
compared to NC group; while Talc control and 
DOX+Talc control were showed not significant (ns) 
level when compared with DOX control. In Talc+PCM 
control and DOX+Talc+PCM control were 
demonstrated significant level (p<0.001) level of HDL 
as related with DOX control(Table no. 2). 
LDL (mg/dl) 
The DOX control were displayed significantly upward 
(p<0.001) level of LDL and Talc control were showed 
not significant (ns) level of LDL when compared with 
NC; on the other hand if Talc control and DOX+Talc 
control were compared with DOX control it showed 
not significant (ns) level of LDL. DOX+Talc+PCM 
control were demonstrated significant level (p<0.001) 
level of LDL as compared with DOX control(Table 
no. 2). 
Cal2+ ion (m.eq/L) 
The DOX control and Talc control were displayed 
significantly downward (p<0.001) level of Calcium ion 
as compared to NC group; while if Talc control, PCM 
control, DOX+Talc control and Talc+PCM control 
were showed not significant (ns) level of Calcium ion 
when compared to DOX Control. In DOX+Talc control 
and DOX+Talc+PCM control were demonstrated 
significantly increased level (p<0.001) of Calcium ion 
when compared to DOX Control(Table no. 2). 
Na+ ion(m.eq/L) 
The DOX control and Talc control were illustrated not 
significant (ns) level of Sodium ion as compared to NC 
group; while if Talc control, PCM control, DOX+Talc 
control, Talc+PCM control, DOX+Talc and 
DOX+Talc+PCM were also displayed not significant 
(ns) level of Sodium ion when compared to DOX 
Control(Table no. 2).  
K+ ion (m.eq/L) 
The DOX control were demonstrated not significant 
(ns) level and Talc control were displayed significantly 
upward (p<0.001) level of Potassium ion as compared 
to NC group; while if Talc control, DOX+Talc control 
and Talc+PCM control were compared to DOX 
Control it illustrated significantly increased (p<0.001) 
level of Potassium ion. In PCM control and 
DOX+PCM control were showed not significant (ns) 
level and DOX+Talc+PCM control were demonstrated 
significantly increased level (p<0.05) of Potassium ion 
when compared to DOX Control(Table no. 2). 
CPK-MB (U/L) 
The DOX control Talc control were displayed 
significantly upward (p<0.001) level of CPK-MB as 
compared to NC group; while if Talc control, PCM 
control, DOX+Talc control, Talc+PCM control and 
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DOX+Talc+PCM were compared to DOX Control it 
illustrated significant (p<0.001) level of CPK-MB. In 
and DOX+PCM control were demonstrated 
significantly decreased level (p<0.01) of CPK-MB 
when compared to DOX Control(Table no. 1). 
CRP (mg/L) 
The DOX control and Talc control were displayed 
significantly increased (p<0.001) level of CRP as 
compared to NC group; while if Talc control, 
DOX+Talc control were compared to DOX Control it 
illustrated not significant (ns) level of CRP. PCM 
control and Talc+PCM control were significantly 
decreased (p<0.001) level of CRP when compared to 
DOX Control while In DOX+Talc+PCM control were 
demonstrated significantly diminished level (p<0.01) 
of CRP when compared to DOX Control(Table no. 1). 
Troponin-T (U/L) 
The DOX control displayed significantly increased 
(p<0.05) level of Troponin-T and Talc control were 
displayed significantly increased (p<0.001) level of 
Troponin-Tas compared to NC group; while if Talc 
control, DOX+Talc control, Talc+PCM control and 
DOX+Talc+PCM control were compared to DOX 
Control it illustrated significantly elevated (p<0.001) 
level of Troponin-T when compared to DOX 
Control(Table no. 1). 
 
Table 1:Data showing the effect of Talc on the levels of Blood glucose (mg/dl), Triglyceride (mg/dl), 
Creatinine (mg/dl), CRP (mg/L), Troponin-T (U/L), CPK-MB (U/L) of wistar rats 
 
S.N
o. 
Groups Blood 
glucose 
(mg/dl) 
Triglyceride 
(mg/dl) 
Creatinine 
(mg/dl) 
 CRP (mg/L)  Troponin-T 
(U/L) 
CPK-MB 
(U/L) 
1 Normal 
control (NC) 
73.83±3.43
9 
47.67±2.41
8 
0.620±0.040
4 
1.733±0.066
6 
0.533±0.019
6 
65.83±4.72
9 
2 DOX control  83.50±1.56
5ns 
56.33±1.83
8 ns 
0.988±0.040
3### 
3.083±0.124
9 ### 
1.212±0.205
6# 
295.0±12.7
8 ### 
3 Talc control  240.7±4.63
1*** 
122.7±2.98
5*** 
0.978±0.057
7ns 
2.650±0.147
8 ns 
4.700±0.171
3 *** 
614.7±3.57
5 *** 
4 PCM control  95.83±2.93
7ns 
61.83±1.81
5 ns 
0.650±0.048
3*** 
1.733±0.066
6*** 
0.7667±0.09
71 ns 
173.8±2.49
6 *** 
5 DOX +Talc 
control 
213.3±9.97
2*** 
60.83±2.28
6 ns 
1.022±0.030
4ns 
2.850±0.133
5 ns 
3.683±0.162
1*** 
198.3±12.4
9*** 
6 DOX +Met 
control 
93.67±3.74
8 ns 
69.00±2.74
5* 
0.681±0.009
4*** 
2.517±0.135
2* 
1.075±0.162
4 ns 
208.7±30.8
0 ** 
7 Talc+ PCM 
control 
233.3±6.28
0*** 
80.00±3.15
2*** 
0.723±0.028
3*** 
2.250±0.117
6*** 
2.983±0.140
0*** 
200.8±12.8
1*** 
8 DOX+Talc+P
CM control 
225.0±3.65
1*** 
68.33±1.02
2* 
0.815±0.016
6* 
2.367±0.143
0** 
2.283±0.113
8*** 
129.0±7.23
4*** 
Values are expressed as mean ± SEM (N= 6).  (#) Groups as compared to normal control, (*) Groups as compared to 
DOX control. ns –no significant; * P<0.05; **P<0.01; ***P<0.001. 
 
Table 2: Data showing the effect of Talc on the levels of Total Cholesterol (mg/dl), HDL (mg/dl), LDL (mg/dl), 
Cal2+ion (m.eq/L), Na+ion (m.eq/L), K+ion (m.eq/L)  of wistar rats 
 
S.N
o. 
Groups Total 
Cholesterol 
(mg/dl) 
HDL (mg/dl) LDL 
(mg/dl) 
Cal2+ion 
(m.eq/L) 
Na+ion 
(m.eq/L) 
K+ion 
(m.eq/L) 
1 Normal 
control (NC) 
72.00±3.642 21.67±0.881
9 
45.0±1.713 9.233±0.06
66 
151.0±0.730 4.050±0.076
3 
2 DOX control  127.5±2.141
### 
12.83±0.600
9### 
59.17±1.956
### 
8.10±0.243
### 
152.5±0.763
8ns 
4.383±0.186
9 ns 
3 Talc control  110.8±3.070
* 
14.33±1.022n
s 
52.67±1.606 
ns 
7.667±0.15
6 ns 
148.5±1.607 
ns 
6.383±0.233 
*** 
4 PCM control  71.50±1.875
*** 
23.00±1.155*
** 
43.67±1.476
*** 
7.633±0.08
8 ns 
152.5±0.763 
ns 
4.683±0.074
9 ns 
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5 DOX +Talc 
control 
105.8±2.301
** 
11.67±0.557
8 ns 
59.67±1.926 
ns 
9.100±0.10
65 *** 
150.7±0.666 
ns 
6.617±0.192
2*** 
6 DOX +Met 
control 
96.67±6.280
*** 
18.17±0.792
3** 
47.50±2.487
*** 
8.650±0.07
63 ns 
151.3±1.145 
ns 
4.733±0.111 
ns 
7 Talc+ PCM 
control 
93.17±2.12*
** 
23.33±0.881
9*** 
48.33±1.726
** 
7.750±0.12
5 ns 
150.7±1.430 
ns 
6.467±0.154*
** 
8 DOX+Talc+P
CM control 
105.0±4.830
** 
19.50±0.428
2*** 
40.67±1.116
*** 
9.050±0.04
28 *** 
152.8±0.945 
ns 
5.262±0.241* 
Values are expressed as mean ± SEM (N= 6).  (#) Groups as compared to normal control, (*) Groups as compared to 
DOX control. ns –no significant; * P<0.05; **P<0.01; ***P<0.001. 
 
Discussion 
 
Cardiac remodelling is defined as genome expression, 
molecular, cellular, and interstitial changes that 
manifest clinically as changes in the size, shape, and 
function of the heart after cardiac injury [1] or 
increased cardiac load.Type 2 diabetes is associated 
with significantly higher risk of heart failure (HF), 
coronary artery disease (CAD) and cardiac remodelling 
[15].The current American Heart Association, heart 
failure classification schema designates the presence of 
diabetes mellitus as stage a heart failure, which raises 
the risk of developing stage B heart failure or 
asymptomatic left ventricular (LV) dysfunction [16]. 
Individuals with diabetes frequently have LV 
remodelling; both increased LV mass and dilatation 
have been reported [17]; Researchers have also 
observed that factors associated with insulin resistance 
syndrome predate the development of LV systolic 
dysfunction by 2 decades, adjusting for ischemic heart 
disease and other risk factors [18].Doxorubicin is an 
anti-tumour drug that is useful in treating several types 
of cancer, although its clinical use has been restricted 
due to cardiomyopathy induced by dose-dependent 
cardiotoxicity. Once cardiomyopathy occurs, treatment 
options are few, and doxorubicin-induced heart failure 
is usually refractory to conventional therapy. Hence, to 
evaluate Talc effect on doxorubicin-induced 
cardiomyopathy is the goal [19]. In the present study 
DOX control rats were not increased the level of 
glucose nor triglyceride, on the other hand Talc treated 
rats were demonstrated the significantly (p<0.001) 
high blood glucose level, altered insulin level, 
significant (p<0.001) higher circulating levels of 
triglycerides and lower high-density lipoprotein 
(HDL)-cholesterol concentrations and commonly 
manifest the metabolic syndrome [20]. The metabolic 
syndrome is a predictor of future risk of cardiovascular 
disease[21]. Specifically, it is widely recognized that 
higher levels of small dense low-density lipoprotein 
particles are a major contributor of increased risk for 
cardiovascular disease in insulin-resistant patients [22]. 
The association of different lipid fractions (especially 
the total cholesterol to HDL-cholesterol ratio) with 
incident heart failure is not the same as that for incident 
atherosclerotic cardiovascular events [23]. Evidence 
supports that higher triglyceride levels [24] or higher 
non-HDL–cholesterol levels [25]increase the risk of 
developing heart failure, perhaps because of the 
presence of insulin resistance that predisposes to 
metabolic changes characterized by impaired 
myocardial fatty acid oxidation and greater uncoupling 
of mitochondrial proteins in the heart [26]. Therefore in 
the Talc treated rats an insulin-resistant condition is 
developed which decreased uptake of myocardial 
glucose [27], resultant myocardial cells incapable to 
metabolize pyruvate, so that lipid accumulation in the 
myocardium is started [28]. However, the mechanisms 
by which free fatty acid metabolism and glucose 
oxidation are interrelated are quite complex [29]. 
Increased activation of different isomers of protein 
kinase C has been noted to play a role in inhibition of 
insulin secretion by free fatty acids [30]. On the other 
hand, hyperinsulinemia in diabetic patients is also 
associated with increased free fatty acid levels, 
elevated heart rate, and increased activation of 
sympathetic nervous system; all these factors 
subsequently lead to cardiac hypertrophy and 
intracellular accumulation of triglycerides. In the 
presence of hyperinsulinemia and insulin resistance, 
the heart has also been shown to reduce protein 
degradation, which may then promote myocardial 
hypertrophy [31]. In addition, dyslipidemia and 
production of free radicals result in alteration of 
genetic transcription factors and coding, which 
subsequently alters the translation of nucleoprotein 
genes such as those in the renin-angiotensin system 
(RAS) and IGF-1. Increased expression of RAS genes 
promotes insulin resistance, whereas greater expression 
of the IGF-1 gene increases sensitivity of cardiac 
myocytes to calcium concentrations and increases 
myocardial contractility. IGF-1 also acts synergistically 
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with angiotensin II in promoting cellular and 
myocardial hypertrophy [32].Doxorubicin intoxication 
caused a significant increase (p<0.001) in the plasma 
concentration of Cholesterol, LDL and triglycerides 
and reduction in HDL; similar result was illustrated by 
Talc treated wistar rats. This indicates that doxorubicin 
and Talc may be interfering with metabolism or 
biosynthesis of lipids. Alterations in lipid metabolism 
and serum levels of cholesterol, triglyceride and LDL 
are some of the biochemical indices that are often used 
in the prediction of cardiovascular disease risk [33]. 
Diabetes mellitus is frequently associated with 
impaired lipid metabolism such as elevated cholesterol 
and triglycerides (TG) and abnormalities in serum 
lipoproteins [34]. Talc treated rats showed elevation of 
blood glucose level leads disturbance in triglyceride 
level of blood which further interfere with cholesterol, 
lipid metabolism, lowered HDL and increased LDL 
level; that could generate cardiac dysfunction in Wistar 
rats and by the time may induces cardiac remodelling 
like condition.  A high level of LDL can be suggestive 
of medical problems such as diseases of cardiovascular 
system, also the higher the level, the higher the risk for 
coronary artery disease in Talc treated rats [35, 36]. 
Lipids play an important role in the pathogenesis of 
myocardial ischemia. Hypercholesterolemia and 
hypertriglyceridemia are the risk factor for the 
development of myocardial ischemia. Increased levels 
of blood cholesterol and their accumulations in the 
heart are well associated with myocardial damage 
[37].Creatinine is filtered out of the blood by the 
kidney and is a direct measure of renal excretory 
function. If the filtering by the kidney is deficient, 
plasma levels rises above normal, the urine levels 
reduces. Serum creatinine concentration increases 
when more than 50% of renal function has been lost 
[38]. Although creatinine, like urea, is not generally 
considered to be an important uremic toxin, both 
compounds have been shown experimentally to be 
toxic in acutely uremic rats [39].It is however a known 
fact that kidney function is compromised in 
uncontrolled diabetes mellitus. Glycosuria, which is a 
pertinent diagnostic feature of diabetes, causes 
dehydration via glucose osmotic diuresis. This 
dehydration is accompanied with severe loss of 
electrolytes including sodium, potassium, calcium, 
chloride and phosphates. A decrease in concentration 
of plasma sodium (hyponatremia) could be suggestive 
of diseases of the liver, kidney or congestive heart 
failure [40]. Persistent low levels of sodium in plasma 
in diabetic rats here is unacceptable because of the 
increased risk of developing congestive heart failure. In 
the present study plasma sodium level were slightly 
decreased in Talc control, but on comparison with 
normal control and DOX control it were not significant 
(ns). Potassium depletion inhibits insulin secretion and 
is associated with glucose intolerance, whereas 
potassium infusion and hyperkalemia increase the 
secretary rate of insulin by changing the membrane 
potential of pancreatic beta cells [41]. In the current 
protocol Talc control showed the significant increased 
level of plasma Potassium level which indicated that 
Talc treated Wistar rats trying to maintain the insulin 
level by changing potential of beta cells. 
In addition, Ca2+handling alterations in vascular 
smooth muscle cell (VSMCs) contribute to blood 
vessel dysfunction associated with diabetes. VSMCs 
provide not only structural integrity to the vessels but 
also actively regulate arterial tone and local blood 
pressure via diverse Ca2+ signalling pathways [42]. 
Vascular dysfunction is a distinctive phenotype found 
in both types of diabetes and likely contributes to the 
high incidence of stroke and heart attack, not to 
mention organ damage, such as retinopathy and 
nephropathy, that is observed in diabetic patients [43, 
44], The CK system of isoenzymes consists of CK-
MM, CK-MB, CK-BB, and mitochondrial-CK. Each 
subunit of the dimeric CK is regulated by a distinct 
gene, and expressed in a tissue-specific manner. In 
humans and animals, CK-MB is found predominately 
in the myocardium; with concentration ranges from 5 
to 30% of the total CK activity of the heart. The largest 
portion of the heart is composed of CK-MM. CK-MB, 
a golden standard marker of myocyte injury or death, 
leaks out from myocardium due to disintegration of the 
contractile apparatus and increased sarcoplasmic 
permeability. When ischemia destructs cell membrane, 
these enzymes are leaked out of cells[45]; so the level 
shows the injury rate and cell necrosis [46]. In Talc 
control and DOX control significantly (p<0.001) 
elevated level of CK-MB clearly said that Talc may 
responsible for the myocardial cell injury or membrane 
integrity in current research. C-reactive protein (CRP) 
as a sensitive marker of inflammation has been widely 
studied, its level regulated primarily by the function of 
cytokines, such as interleukin-6 (IL-6). It binds to a 
wide variety of substances, such as microbial 
polysaccharide, phosphatidylcholine, and damaged cell 
membrane. CRP also enhances the activity of 
phagocytic cells and activates the classical complement 
pathway [47]. The differences seen in CRP 
concentrations between the normal control, DOX 
control and Talc controls remained highly significant 
after the adjustment for hypertension, diabetes. These 
increases in CRP levels also reflect the severity of 
coronary disease [48]. Our data of the elevated CRP 
levels in the wistar rats with increased levels of LDL 
may raise the possibility of the cardiac disorder. 
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Cardiac troponin is regulatory proteins that control the 
calcium mediated interaction of actin and myosin 
resulting in contraction and relaxation of striated muscle. 
Greaser et al. demonstrated that the troponin complex 
comprised three distinct proteins: troponin C (TnC), for 
binding Ca2+ and regulating thin filament activation; 
troponin I (TnI), for inhibiting actin-activated myosin 
ATPase activity; and troponin T (TnT), for binding 
tropomyosin (Tm) [49]. Troponin I and T are two proteins 
of the thin filament regulatory system of the contractile 
complex of heart and skeletal muscle. TnI is encode by 
three different genes that are differentially expressed by 
various muscle tissues. Cardiac troponin I (cTnI) is 
uniquely specific for the heart, containing a 31-amino acid 
sequence on its N-terminus that differentiates it from the 
fast and slow skeletal forms. Troponin T is also expressed 
by three different genes, resulting in slow and fast skeletal 
isoforms and a cardiac (cTnT) form [50, 51]. Cardiac 
troponin T is an established biochemical marker of 
myocyte damage which can be used to assess myocyte 
damage from myocardial infarction [52].Increased TnT in 
the circulation translates to heart injury. Troponin predicts 
the occurrence of clinically significant LV dysfunction at 
least 3 months in advance [53, 54]. The observation that 
Troponin T concentrations are significantly increased 
(p<0.001) in the DOX and Talc treated wistar rats, which 
clearly indicated that may some injury happened in 
myocardial wall, previous researcher gave us various case 
study that supported protocol results.Cardiac troponin 
plays a crucial role in the diagnosis of myocardial 
necrosis. According to the universally accepted definition, 
myocardial infarction is diagnosed when blood levels of 
sensitive and specific biomarkers such as cTn or CK-MB 
are increased in the clinical setting of acute myocardial 
ischemia [55-56]. Although cTnT and cTnI increase in 
blood reflect injury leading to necrosis of myocardial 
cells, they do not provide any clues with respect to the 
underlying disease mechanism. Various possibilities have 
been suggested for the release of structural proteins from 
the myocardium, including normal turnover of myocardial 
cells, apoptosis, cellular `release of troponin degradation 
products, increased cellular wall permeability, formation, 
and release of membranous blebs and myocyte necrosis. 
 
Conclusion 
 
In the conclusion, it can be say that due to increased 
plasma glucose and Triglyceride level in the blood, insulin 
resistance may occur; it mayalteredthe lipid metabolism 
which generated the ROS production in heart wall and 
deposited fatty acid in blood vessels wall this may 
changes the blood flow; therefore blood pressure is 
increased and activation of rennin angiotensin system 
occur, may deposition of fatty acid damage the blood 
vessel wall.By altering Troponin T, CRP; Talc may 
stimulate the vascular inflammation by various circulating 
proinflammatory cytokines such as interleukin-6, 
interleukin 1-beta. These cytokines are responsible to 
generate the NOS expression and nitrite production which 
produce ROS formation and subsequent MAPK 
development may lead oxidation of myofilaments and 
induced cardio-myocyte apoptosis; furthermorethis may 
promote the diabetes cardiomyopathy and if this condition 
retain for long time it will lead cardiac remodelling,but 
through intensive research is required for our 
understanding of the role of Talc as a promoter of cardiac 
remodelling, it represent attractive but challenging targets 
for the future. 
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